Cancer Genetics Announces Closing of Public Offering of 1,500,000 Shares of Common Stock
By Jamie on August 19 2013
RUTHERFORD, NJ (August 19, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the closing of its previously announced public offering of 1,500,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Cancer Genetics from the […]
Continue ReadingCancer Genetics Announces Pricing of Public Offering of 1,500,000 Shares of Common Stock
By Italia on August 13 2013
The Company’s common stock to begin trading on NASDAQ, effective Wednesday August 14, 2013 RUTHERFORD, NJ (August 13, 2013): Cancer Genetics, Inc. (NASDAQ: CGIX), a diagnostics company focused on developing genomic-based, oncology tests and services, today announced the pricing of its public offering of 1,500,000 shares of its common stock at a price to the […]
Continue ReadingCancer Genetics Announces Second Quarter 2013 Financial Results
By Italia on August 5 2013
Frst quarter revenue increased 60% YoY Excluding grant revenue, quarterly revenue grew 90% YoY Gross margin improved 30% from 5% in the year ago period Quarterly clinical test volume increased 97% YoY RUTHERFORD, NJ, August 5, 2013 — Cancer Genetics, Inc. (OTCQB: CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based cancer diagnostics, reported […]
Continue Reading